Thursday 21 September |
| 07:00-20:00 | | Registration
|
| 07:30-08:00 | | Breakfast for Working Group Attendees Pacific Foyer, King Willem Alexander on 1st Floor, First Floor Lobby, Amazon Foyeer
|
| 08:00-09:30 | | ESPE Working Group on Disorders of Sex Development Chair(s): Tülay Güran (Istanbul, Turkey) Atlantic
|
| 08:00 | | Introduction |
| 08:05 | | Case Presentation |
| 08:15 | | Case presentation |
| 08:25 | | Androgen insensitivity syndrome Type 1 |
| 08:50 | | Androgen insensitivity syndrome Type 2 |
| 09:15 | | Discussion with attendees |
| 09:25 | | Concluding Remarks |
| 08:00-09:30 | | ESPE Working Group on Obesity Chair(s): Erica van den Akker (Rotterdam, The Netherlands) Pacific
|
| 08:00 | | The ESPE Obesity Working Group |
| 08:20 | | Environmental contributions to obesity development |
| 08:40 | | New treatment in children and adolescents with obesity |
| 09:00 | | Overweight and obesity in European Young Children: ToyBox-study lessons |
| 09:20 | | Q&A |
| 08:00-09:30 | | ESPE Bone and Growth Plate Working Group Chair(s): Evelien Gevers (London, UK) Yangtze 1&2
|
| 08:00 | | Radiology of rare and less rare skeletal dysplasia |
| 08:30 | | Genetics of rare skeletal dysplasia |
| 09:00 | | 2x clinical case from working group members |
| 08:00-09:30 | | ESPE Working Group on Diabetes Technology Chair(s): Moshe Phillip (Petah Tikva, Israel) Mississippi
|
| 08:00 | | Introduction |
| 08:05 | | Stage 1/Stage 2 T1DM – how do we monitor outside of clinical studies? |
| 08:25 | | CGM use in Stage 2 T1DM |
| 08:45 | | Immune intervention of newly diagnosed of T1DM – where are we today? |
| 09:05 | | Discussion - Round Table |
| 08:00-09:30 | | ESPE Working Group on Paediatric and Adolescent Gynaecology Chair(s): Lourdes Ibanez Toda (Barcelona, Spain) King Willem Alexander Auditorium
|
| 08:00 | | Early puberty: connecting nutritional status and pubertal activation |
| 08:25 | | Environmental programming of early pubertal onset |
| 08:50 | | Management of early puberty : adaptation or overmedicalization? |
| 08:00-09:30 | | ESPE Working Group on Gender Incongruence Chair(s): Sabine Hannema (Amsterdam, The Netherlands) Amazon
|
| 08:00 | | Gender dysphoria and autism, implications for diagnosis and decision making |
| 08:30 | | Animal models of transgender care, advantages and drawbacks |
| 09:00 | | Moral dilemmas surrounding puberty suppression in transgender adolescents’ |
| 08:00-09:30 | | ESPE Working Group on Turner Syndrome Chair(s): Janielle van der Velden (Nijmegen, The Netherlands) Everest 1&2
|
| 08:00 | | Challenges and opportunities in prenatal and postnatal diagnosis of Turner Syndrome & Parents’ Testimony |
| 08:10 | | Medical aspects |
| 08:25 | | Psychological aspects |
| 08:35 | | Ethical considerations |
| 08:45 | | Panel discussion (interactive) |
| 09:15 | | I-TS & pubertal induction study |
| 09:25 | | Update form TSWG and Disclosure |
| 09:30-10:00 | | Refreshment Break, Posters and Exhibition Exhibition Hall
|
| 10:00-10:15 | | Opening Ceremony King Willem Alexander Auditorium
|
| 10:15-10:45 | | Plenary 1: Sex Differences in the Brain: Intersection of the Endocrine, Immune and Nervous Systems Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands) & Sabine Hannema (Amsterdam, The Netherlands) King Willem Alexander Auditorium
|
| 10:15 | PL1 | Sex Differences in the Brain: Intersection of the Endocrine, Immune and Nervous Systems |
| 10:45-11:15 | | Awards 1 - Henning Andersen Prizes Chair(s): Nils Krone (Sheffield, UK) King Willem Alexander Auditorium
|
| 10:45 | | Awards 1 - Henning Andersen Prizes |
| 11:25-12:55 | | Symposium 1 - Disorders of Sex Development Chair(s): Angela Lucas Herald (Glasgow, UK) & David Zangen (Jerusalem, Israel) Atlantic
|
| 11:25 | S1.1 | Life-long care for people with 46,XY DSD |
| 11:55 | S1.2 | Regulation of germ cell fate during sex determination |
| 12:25 | S1.3 | Pathogenesis of testicular dysfunction in Klinefelter syndrome |
| 11:25-12:55 | | Symposium 2 - Hypothalamo-pituitary disorders Chair(s): Mariacarolina Salerno (Naples, Italy) & Roland Pfaffle (Leipzig, Germany) Pacific
|
| 11:25 | S2.1 | Novel imaging techniques in pituitary tumours |
| 11:55 | S2.2 | Stem cells in the pituitary |
| 12:25 | S2.3 | Pioneer transcription factors |
| 11:25-12:55 | | Symposium 3 - Endocrine effects of cancer treatment Chair(s): Hoong-wei Gan (London, UK) & Hanneke van Santen (Utrecht, The Netherlands) Mississippi
|
| 11:25 | S3.1 | Safety of GH treatment in cancer survivors |
| 11:55 | S3.2 | Surveillance for endocrine disease in Childhood Cancer Survivors |
| 12:25 | S3.3 | Fertility preservation in children with cancer |
| 11:25-12:55 | | Symposium 4 - Novel insights and innovations in diabetes Chair(s): Jacques Beltrand (Paris, France) & May Ng (Liverpool, UK) Yangtze 1&2
|
| 11:25 | S4.1 | Role of alpha cells in islet function |
| 11:55 | S4.2 | Delaying the development of T1DM |
| 12:25 | S4.3 | Physical interaction between beta and delta cells |
| 11:25-12:25 | | Yearbook 1 Chair(s): Christa Flück (Bern, Switzerland) Amazon
|
| 11:25 | YB1.1 | Global Health for the Paediatric Endocrinologist |
| 11:37 | YB1.2 | Type 2 Diabetes, Metabolic Syndrome and Lipids |
| 11:49 | YB1.3 | Obesity and Weight Regulation |
| 12:01 | YB1.4 | Adrenal |
| 12:13 | YB1.5 | The Year in Science & Medicine |
| 12:55-14:25 | | Lunch, posters and exhibition Exhibition Hall
|
| 13:15-14:15 | | Satellite Symposium 1 For more information please see satellite programme
|
| 13:15-14:15 | | Satellite Symposium 2 For more information please see satellite programme
|
| 14:25-15:55 | | How do I…? 1 Chair(s): Naomi Weintrob (Tel Aviv, Israel) & Johnny Deladoëy (Montréal, Canada) King Willem Alexander Auditorium
|
| 14:25 | HDI1.1 | How do I manage abnormal thyroid function tests in the newborn? |
| 14:55 | HDI1.2 | How do I use AMH in paediatric practice? |
| 15:25 | HDI1.3 | How do I manage a child with hypercalcemia? |
| 14:25-14:55 | | Rapid Free Communications 1: Adrenals and HPA Axis Chair(s): Christa Flück (Bern, Switzerland) & Li Chan (London, UK) Pacific
|
| 14:25 | RFC1.4 | Unfavorable Body Composition in Children with Premature Adrenarche: Implications for Metabolic Health |
| 14:30 | RFC1.3 | The chimeric CYP21A1P/CYP21A2 and TNXA/TNXB gene deficiencies in patients with Congenital Adrenal Hyperplasia |
| 14:35 | RFC1.5 | The effect of storage and temperature on the stability of steroid hormones in dried blood spots |
| 14:40 | RFC1.1 | Lack of NAD(P)+ transhydrogenase activity in patients with primary adrenal insufficiency due to NNT mutations |
| 14:45 | | Clinical and genetic characteristics of 42 Chinese paediatric patients with X-Linked Adrenal Hypoplasia Congenita |
| 14:50 | RFC1.2 | Interlaboratory comparison of LC-MS/MS measurements of 11 relevant steroid hormones in 27 DSD patients |
| 14:25-14:55 | | Rapid Free Communications 2: Bone, growth plate and mineral metabolism Chair(s): Evelien Gevers (London, UK) & Wolfgang Högler (Linz, Austria) Mississippi
|
| 14:25 | RFC2.1 | Identification of novel genes including NAV2 associated with isolated tall stature |
| 14:30 | RFC2.2 | Familial pseudohypoparathyroidism type IB associated with an SVA retrotransposon insertion in the GNAS locus. |
| 14:35 | RFC2.3 | High incidence of Chiari type I anomalies on MRI in young patients with X-linked hypophosphatemic rickets (XLHR) |
| 14:40 | RFC2.4 | Documentation of inactivating PTH/PTHrP Signaling Disorders (Pseudohypoparathyroidism) cases in EuRRECa / EuRR-Bone: a challenging, but worthwhile journey |
| 14:45 | RFC2.5 | Growth in young children with X-linked hypophosphatemia treated with burosumab |
| 14:50 | RFC2.6 | Short term side effects of first bisphosphonate infusion in children with different underlying bone pathologies. |
| 14:25-14:55 | | Rapid Free Communications 3: Fat, metabolism and obesity 1 Chair(s): Francesco Chiarelli (Chieti, Italy) & Senthil Senniappan (Liverpool, UK) Yangtze 1&2
|
| 14:25 | RFC3.1 | Fasting and meal-related zonulin serum levels in a large cohort of obese children and adolescents: a cross sectional study |
| 14:30 | RFC3.2 | Reduced central sensitivity to thyroid hormones in children and adolescents with overweight or obesity and impaired glucose tolerance. |
| 14:35 | RFC3.3 | Early Corneal Nerve Loss in Children with Melanocortin 4 Receptor (MC4R) Gene Mutation Related Obesity |
| 14:40 | RFC3.4 | Effect of maternal diet and breastfeeding on growth and distribution of adiposity from birth up to 12 months: data from the European LIFE-MILCH project |
| 14:45 | RFC3.5 | Multi-omics Reveals molecule target Underlying Adolescent obesity with metabolic syndrome |
| 14:50 | RFC3.6 | Glucocorticoid-mediated leptin secretion from human adipocytes is dependent on glucose availability |
| 14:25-14:55 | | Rapid Free Communications 4: Growth and syndromes (to include Turner syndrome) Chair(s): Cheri Deal (Montréal, Canada) & Janielle van der velden (Nijmegen, The Netherlands) Atlantic
|
| 14:25 | RFC4.1 | Functional networks reveal pathways linking early growth to childhood blood pressure in the Manchester BabyGRO Study |
| 14:30 | RFC4.2 | Molecular genetic diagnosis in children with Idiopathic Short Stature: Single Center Experience |
| 14:35 | RFC4.3 | Aromatase inhibitors: an effective and safe option for height increment in boys with growth hormone deficiency? |
| 14:40 | RFC4.4 | Genetic findings in short Turkish children born to consanguineous parents |
| 14:45 | RFC4.5 | Real-world safety and effectiveness of vosoritide: Results from an early access program in France |
| 14:50 | RFC4.6 | Results from the PROPEL 2 dose-finding study: oral infigratinib leads to significant increases in height velocity with good tolerability in children with achondroplasia |
| 14:25-14:55 | | Rapid Free Communications 5: Diabetes and insulin 1 Chair(s): Paul Voorhoeve (Nijmegen, The Netherlands) & Marianna Rachmiel (Zerifin, Israel) Amazon
|
| 14:25 | RFC5.1 | Tear proteomics profile in children and adolescents with type 1 diabetes mellitus |
| 14:30 | RFC5.2 | Comparison of Optical Coherence Tomography Angiography Findings in Children with Type 1 Diabetes Mellitus and Autoimmune Thyroiditis with Healthy Children |
| 14:35 | RFC5.3 | 3 Screen ICA ELISA–A new tool to identify pre-clinical diabetes in first-degree relatives of patients with type 1 diabetes (pre-d1abetes study) |
| 14:40 | RFC5.4 | Effect of probiotic on glycemic control in children with type 1 diabetes : A randomized controlled trial |
| 14:45 | RFC5.5 | Syndrome of hypoglycemia unawareness in children with type 1 diabetes: clinical contribution of Clark and Gold questionnaire |
| 14:50 | RFC5.6 | Do females with Type 1 Diabetes have puberty earlier? |
| 14:55-15:55 | | Free Communications 1: Adrenals and HPA Axis Chair(s): Christa Flück (Bern, Switzerland) & Li Chan (London, UK) Pacific
|
| 14:55 | FC1.1 | Investigating intergenerational effects of glucocorticoids |
| 15:05 | FC1.2 | The pathophysiologic response of central nervous system due to differently impaired steroidogenesis |
| 15:15 | FC1.4 | Response to Crinecerfont Treatment in Adolescents with Classic Congenital Adrenal Hyperplasia Is Correlated with Elevated Baseline Hormone Concentrations but Not Glucocorticoid Dose |
| 15:25 | FC1.3 | Generation and Characterization of a novel Humanized CYP21A2 Knock-in Mouse Model for Congenital Adrenal Hyperplasia |
| 15:35 | FC1.5 | Management of congenital adrenal hyperplasia in the first 90 days of life: a multi-centre I-CAH analysis of contemporary practice |
| 15:45 | FC1.6 | Cardiovascular risk profile in adult patients with congenital adrenal hyperplasia: a cross-sectional study |
| 14:55-15:55 | | Free Communications 2: Bone, growth plate and mineral metabolism Chair(s): Evelien Gevers (London, UK) & Wolfgang Högler (Linz, Austria) Mississippi
|
| 14:55 | FC2.1 | Hearing loss in pseudohypoparathyroidism (inactivating PTH/PTHRP Signaling Disorder): a prospective study to assess prevalence and predictive factors of hearing loss in 44 patients affected with iPPSD/PHP |
| 15:05 | FC2.2 | First Results of the Global ALPL Gene Variant Classification Project |
| 15:15 | FC2.3 | Hyperparathyroidism after three years of burosumab in children affected with x-linked hypophosphatemia |
| 15:25 | FC2.4 | A real-world study in Germany and Switzerland regarding renal health in children with X-linked hypophosphatemia |
| 15:35 | FC2.5 | Generation of novel genetic zebrafish models and using RNA-seq analysis to explore the role of ankrd11 gene on bone growth |
| 15:45 | FC2.6 | Human breast milk-derived exosomes promote growth plate cell lines in vitro |
| 14:55-15:55 | | Free Communications 3: Fat, metabolism and obesity 1 Chair(s): Francesco Chiarelli (Chieti, Italy) & Senthil Senniappan (Liverpool, UK) Yangtze 1&2
|
| 14:55 | FC3.1 | Early childhood height and weight development in children with monogenic obesity: A European multicenter cohort study |
| 15:05 | FC3.2 | Analysis of ligand- and mutation-dependent signaling of the melanocortin 4 receptor (MC4R): an example of the relevance of differential signaling (bias signaling) |
| 15:15 | FC3.3 | Frequency of Obesity-Related Gene Variants in a European Population With Early-Onset, Severe Obesity |
| 15:25 | FC3.4 | A Novel Mutation in DYRK1B Associated With Abdominal Obesity Metabolic Syndrome 3 (AOMS3) |
| 15:35 | FC3.5 | Early corneal nerve loss in children with obesity and type 2 diabetes |
| 15:45 | FC3.6 | Impact of Setmelanotide on Future Metabolic Syndrome Risk in Pediatric Patients With Bardet-Biedl Syndrome |
| 14:55-15:55 | | Free Communications 4: Growth and syndromes (to include Turner syndrome) Chair(s): Cheri Deal (Montréal, Canada) & Janielle van der velden (Nijmegen, The Netherlands) Atlantic
|
| 14:55 | FC4.1 | Heterozygous Null Mutations in FLNB as a Cause of apparent isolated Short Stature in Chinese Children |
| 15:05 | FC4.2 | Genetic and phenotypic features of children with familial tall stature |
| 15:15 | | Pathogenic variants in GHSR cause short stature and growth hormone neurosecretory dysfunction; results from a large case series |
| 15:25 | | Growth failure in aggrecan haploinsufficiency is due to a decrease in growth plate matrix volume and hypertrophic cell size |
| 15:35 | | From thalidomide embryopathy to genetic defects of the upper limb, internal organs, cerebral midline, and pituitary: The phenotypic spectrum of SALL4 |
| 15:45 | | Persistence of Growth Promoting Effects in Infants and Toddlers with Achondroplasia: Results in Children Aged Over 2 Years Old from a Phase II Extension Study with Vosoritide |
| 14:55-15:55 | | Free Communications 5: Diabetes and insulin 1 Chair(s): Paul Voorhoeve (Nijmegen, The Netherlands) & Marianna Rachmiel (Zerifin, Israel) Amazon
|
| 14:55 | FC5.1 | Diabetes mellitus and gender incongruence: Worse metabolic control in type 1 and higher mental health issue rates in type 1 and 2 diabetes – a DPV registry study |
| 15:05 | FC5.2 | Nailfold capillaroscopy: An alternative non-invasive tool for evaluating microvascular involvement in children with type 1 diabetes |
| 15:15 | FC5.3 | How feasible is it to meet the Time in Tight Range (TITR) target with Automatic Insulin Delivery (AID)?: 2128-day real-world data from a single center |
| 15:25 | FC5.4 | Changes of intestinal flora in children with type 1 diabetes mellitus and its related immune mechanism |
| 15:35 | FC5.5 | Sleep Characteristics, Glycemic Control, and Endothelial Function in Adolescents and Young Adults with Type 1 Diabetes |
| 15:45 | FC5.6 | Post-Hypoglycemic Hyperglycemia Are Highly Relevant Markers For Stratification Of Glycemic Variability and Remission Status Of Pediatric Patients With New-Onset Type 1 Diabetes. |
| 15:55-16:15 | | Refreshment Break, Posters and Exhibition Exhibition Hall
|
| 16:15-16:45 | | Plenary 2 Chair(s): Stefano Cianfarani (Rome, Italy) & Erica van den Akker (Rotterdam, The Netherlands) King Willem Alexander Auditorium
|
| 16:15 | PL2 | The food environment and the global childhood obesity epidemic: The role of ultra-processed food |
| 16:55-17:40 | | Meet the Expert 1.1 Mississippi
|
| 16:55 | | Management of MEN1 in children and adolescents |
| 16:55-17:40 | | Meet the Expert 2.1 Atlantic
|
| 16:55 | | Informing children about their DSD – when and how? |
| 16:55-17:40 | | Meet the Expert 3.1 Yangtze 1&2
|
| 16:55 | | Uncertainties around diagnosing growth hormone deficiency |
| 16:55-17:40 | | Meet the Expert 4.1 Amazon
|
| 16:55 | | Clinical Management of Prader-Willi Syndrome in infants, children and adolescents |
| 16:55-17:55 | | Ethics in Endocrinology Chair(s): Theo Sas (Rotterdam, The Netherlands) & Marek Niedziela (Poznan, Poland) King Willem Alexander Auditorium
|
| 16:55 | EE1.1 | Ethics of expensive treatments |
| 17:25 | EE1.2 | Should we strive for normality? |
| 17:50-19:20 | | Satellite Symposium 3 For more information please see satellite programme
|
| 17:50-19:20 | | Satellite Symposium 4 For more information please see satellite programme
|
| 17:50-19:20 | | Satellite Symposium 5 For more information please see satellite programme
|
Friday 22 September |
| 07:15-19:30 | | Registration
|
| 08:00-08:30 | | Plenary 3 Chair(s): Agnès Linglart (Paris, France) & Paul van Trotsenburg (Amsterdam, The Netherlands) King Willem Alexander Auditorium
|
| 08:00 | PL3 | Structural and functional development of the adolescent brain |
| 08:15-08:45 | | Industry Expert Forum 1 For more information please see Industry Expert programme
|
| 08:30-09:30 | | Controversy 1 Chair(s): Peter Clayton (Manchester, UK) & Philippe Backeljauw (Cincinnati, USA) King Willem Alexander Auditorium
|
| 08:30 | | Pharmacological manipulation of bone maturation should be used to preserve final height in short children (FOR) |
| 08:30 | | Pharmacological manipulation of bone maturation should NOT be used to preserve final height in short children (AGAINST)." |
| 08:35-09:20 | | Meet the Expert 5.1 Yangtze 1&2
|
| 08:35 | | Management of Pituitary adenomas in Children |
| 08:35-09:20 | | Meet the Expert 6.1 Atlantic
|
| 08:35 | | Approach to Thyroid cancer in Children |
| 08:35-09:20 | | Meet the Expert 7.1 Amazon
|
| 08:35 | | Management of hyperinsulism beyond the acute phase |
| 08:35-09:20 | | Meet the Expert 8.1 Mississippi
|
| 08:35 | | Puberty induction in hypogonadism |
| 08:35-09:20 | | Meet the Expert 1.2 Pacific
|
| 08:35 | | Management of MEN1 in children and adolescents |
| 09:00-09:30 | | Industry Expert Fora 2&3 For more information please see Industry Expert programme
|
| 09:30-11:00 | | Endo-ERN Symposium Chair(s): Olaf Hiort (Lübeck, Germany) & Luca Persani (Milan, Italy) Oceania
|
| 09:30 | | Perspective of Endo-ERN for the next five years |
| 09:40 | | European medicine shortages: How can we avoid a disaster for patients with rare conditions? |
| 10:05 | | It matters - set up of clinical trials in rare diseases |
| 10:35 | | ERNs and clinical trials; the ERICA and Rare Disease Partnership perspective |
| 09:30-10:00 | | Rapid Free Communications 6: Pituitary, neuroendocrinology and puberty 1 Chair(s): Nitash Zwaveling-Soonawala (Amsterdam, The Netherlands) & Paul Dimitri (Sheffield, UK) Pacific
|
| 09:30 | RFC6.1 | Clinical application of LH cut-off value in the diagnosis of CPP according to the international consensus |
| 09:35 | RFC6.2 | Psychosocial Evaluation of Girls with Rapidly Progressive Puberty Presenting with Early Menarche |
| 09:40 | RFC6.3 | Exposure to Per- and Polyfluoroalkyl Substances and Pubertal Assessment by Ultrasound in Norwegian Boys and Girls: Data from the Bergen Growth Study 2 |
| 09:45 | RFC6.4 | Earlier Occurrence of Puberty and Pubertal Hair Development in Boys and Girls - Insights from the DPV Initiative Data |
| 09:50 | RFC6.5 | EFFICACY AND SECURITY OF GONADOTROPIN TREATMENT IN ADOLESCENTS WITH CONGENITAL HYPOGONADOTROPIC HYPOGONADISM |
| 09:55 | RFC6.6 | Evaluation of Serum MKRN3 and DLK1 Concentrations for Predicting Variant Detection in MKRN3 and DLK1Genes in Patients with Central Precocious Puberty |
| 09:30-10:00 | | Rapid Free Communications 7: Sex differentiation, gonads and gynaecology or sex endocrinology Chair(s): Hedi Claahsen (Nijmegen, The Netherlands) & Anna Nordenström (Stockholm, Sweden) Atlantic
|
| 09:30 | RFC7.1 | Penile width increases more clearly than penile length during minipuberty: a longitudinal study of 136 healthy infant boys |
| 09:35 | RFC7.2 | International Evidence-Based Guidelines for PCOS 2023: Recommendations in Adolescent Girls |
| 09:40 | RFC7.3 | Histone code, cryptorchidism,infertility |
| 09:45 | RFC7.4 | Serum steroid metabolome dynamics during infancy: a prospective, longitudinal cohort of healthy boys |
| 09:50 | RFC7.5 | Sex differences in endocrine mechanisms during early human fetal brain development |
| 09:55 | RFC7.6 | Prenatal AnoGenital Distance (AGD) by ultrasonography in 571 fetuses and correlation to postnatal AGD: A longitudinal cohort study of healthy males and females |
| 09:30-10:00 | | Rapid Free Communications 8: Fat, metabolism and obesity 2 Chair(s): Cosimo Giannini (Chieti, Italy) & Thomas Reinehr (Datteln, Germany) Yangtze 1&2
|
| 09:30 | RFC8.1 | A novel heterozygous likely pathogenic variant in GNB1 causing hyperphagia, severe early onset obesity and neurodevelopmental disorder |
| 09:35 | RFC8.2 | Acute rise of leptin after five days of dexamethasone and its association with hunger, fat mass, sleep and fatigue, in children with acute lymphoblastic leukemia |
| 09:40 | RFC8.3 | Higher levels of serum α-Klotho are longitudinally associated with less visceral fat accumulation in apparently healthy girls experiencing weight gain |
| 09:45 | RFC8.4 | Understanding the genetics of early onset obesity in a cohort of children from Qatar |
| 09:50 | RFC8.5 | Effects of leptin knockdown on a human preadipocyte model |
| 09:55 | RFC8.6 | Leukocytes and Neutrophil–Lymphocyte Ratio as Indicators of decreased insulin sensitivity in NGT Overweight and Obese Children with high 1-hour post-load plasma glucose levels |
| 09:30-10:00 | | Rapid Free Communications 9: Diabetes and insulin 2 Chair(s): Kanetee Busiah (Vaud, Switzerland) & Mieke Houdijk (Leiden, The Netherlands) Mississippi
|
| 09:30 | RFC9.1 | The association of dietary glycemic index and load with insulin sensitivity and secretion from early childhood to late adolescence: the QUALITY cohort |
| 09:35 | RFC9.2 | Two new candidate genes,OGDH and FGFR1 discovered in an insulinoma from a fifteen-year-old male |
| 09:40 | RFC9.3 | Impaired Insulin Secretion as a Pathophysiology Underlying Abnormal Glucose Metabolism in Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors: A Study Comparing Glucose Metabolism between ALL Survivors and Simple Obese Children |
| 09:45 | RFC9.4 | Clinical and genetic characteristics of patients suspected to have Maturity-Onset Diabetes of the Young in the Czech Republic |
| 09:50 | RFC9.5 | Insulin secretion defect in children and adolescents with obesity: Clinical and molecular genetic characterization |
| 09:55 | RFC9.6 | Wharton jelly derived mesenchymal stem cells exosomes protect pancreatic beta cells from inflamation |
| 09:30-10:00 | | Rapid Free Communications 10: Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders Chair(s): Rasa Verkauskiene (Kaunas, Lithuania) & Martijn Finken (Amsterdam, The Netherlands) Amazon
|
| 09:30 | RFC10.1 | A novel maternally inherited GNAS variant in a family with hyperphagia and obesity. |
| 09:35 | RFC10.2 | Utility of Continuous Glucose Monitoring (CGM) during pancreatic surgery in patients with Congenital Hyperinsulinism |
| 09:40 | RFC10.3 | Non-coding Variants in HK1 Account for 5% of Cases of Congenital Hyperinsulinism Without an Identified Genetic Cause |
| 09:45 | RFC10.4 | Clinical phenotypes of a multicentric cohort of ROHHAD patients |
| 09:50 | RFC10.5 | Insulinoma in childhood: A multicenter retrospective study of 28 patients |
| 09:55 | RFC10.6 | Two novel mutations in the DCAF17 gene in two Palestinian families with primary amenorrhea revealing molecular genetics in Woodhouse-Sakati syndrome & unique presentation |
| 10:00-11:00 | | Free Communications 6: Pituitary, neuroendocrinology and puberty 1 Chair(s): Nitash Zwaveling-Soonawala (Amsterdam, The Netherlands) & Paul Dimitri (Sheffield, UK) Pacific
|
| 10:00 | FC6.1 | Methylome analysis in idiopathic central precocious puberty girls |
| 10:10 | FC6.2 | The role of body composition and appetite-regulating hormones in idiopathic central precocious puberty and their changes during GnRH analogue therapy. |
| 10:20 | FC6.3 | Is the 24-hour urinary gonadotropin assay an effective diagnostic tool in central precocious puberty? A retrospective study of threshold setting and validation in two cohorts. |
| 10:30 | FC6.4 | Sleeptime-excreted total urinary luteinizing hormone concentrations reveal that the onset of central puberty occurs at around the same time in boys and girls: a longitudinal study |
| 10:40 | FC6.5 | Clinical characteristics of 213 children with early pubertal development complicated with pineal cyst |
| 10:50 | FC6.6 | Serum Kisspeptin and DLK1 levels as a tool for diagnosis and monitoring of central precocious puberty treatment in Thai girls |
| 10:00-11:00 | | Free Communications 7: Sex differentiation, gonads and gynaecology or sex endocrinology Chair(s): Hedi Claahsen (Nijmegen, The Netherlands) & Anna Nordenström (Stockholm, Sweden) Atlantic
|
| 10:00 | FC7.1 | Polygenic scores for testosterone and SHBG are associated with hormone levels in male infants |
| 10:10 | FC7.2 | Mapping the transcriptomic landscape of early human fetal ovary development through a clinically-focused lens |
| 10:20 | FC7.3 | ROS scavengers may improve genital skin healing in boys with hypospadias |
| 10:30 | FC7.4 | The effect of common genetic variants in CYP19A1 on serum Estradiol to Testosterone Ratio in healthy Danish children and adolescents |
| 10:40 | FC7.5 | SGPL1 deficiency, a cause of 46XY DSD and adrenal insufficiency, impairs lipid metabolism and steroidogenesis in Leydig cells |
| 10:50 | FC7.6 | GnRHa response patterns of testis expressed genes in cryptorchid boys |
| 10:00-11:00 | | Free Communications 8: Fat, metabolism and obesity 2 Chair(s): Cosimo Giannini (Chieti, Italy) & Thomas Reinehr (Datteln, Germany) Yangtze 1&2
|
| 10:00 | FC8.1 | Aberrant expression of agouti signaling protein (ASIP) as a new cause of monogenic severe childhood obesity |
| 10:10 | FC8.2 | Frequency of MC4R Pathway Variants in a European Cohort of Individuals With Early-Onset Severe Obesity |
| 10:20 | FC8.3 | Impact of growth hormone therapy on body mass index in childhood-onset craniopharyngioma: a multicenter Italian study in 117 patients. |
| 10:30 | FC8.4 | Irs1 expression in peripheral blood associates with obesity and cardiovascular risk parameters in school-age girls |
| 10:40 | FC8.5 | Impact of Setmelanotide on Metabolic Syndrome Risk in Pediatric Patients With POMC and LEPR Deficiency |
| 10:50 | FC8.6 | Liraglutide treatment in adolescents with extreme obesity - Effects on weight loss in the first 9 months under real-life conditions |
| 10:00-11:00 | | Free Communications 9: Diabetes and insulin 2 Chair(s): Kanetee Busiah (Vaud, Switzerland) & Mieke Houdijk (Leiden, The Netherlands) Mississippi
|
| 10:00 | FC9.1 | Reference values for the insulin response to glucose challenge enable the early detection of emerging (pre)diabetes in children and young adults with obesity |
| 10:10 | FC9.2 | Characterization of pediatric patients with type 2 diabetes and trends in their pharmaceutical management 2000-2022 in German-speaking countries: Analysis based on the DPV registry |
| 10:20 | FC9.3 | A novel case of hypoglycaemia secondary to a pro-insulin processing disorder |
| 10:30 | FC9.4 | The high proportion of INS-MODY in Chinese children with MODY |
| 10:40 | FC9.5 | A case of NARS1 deficiency resulting in diabetes mellitus with liver cirrhosis and pancreatic atrophy |
| 10:50 | FC9.6 | Puberty and Gonadal function in Wolfram Syndrome: A retrospective single centre study |
| 10:00-11:00 | | Free Communications 10: Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders Chair(s): Rasa Verkauskiene (Kaunas, Lithuania) & Martijn Finken (Amsterdam, The Netherlands) Amazon
|
| 10:00 | FC10.1 | Dasiglucagon safety in paediatric participants with CHI |
| 10:10 | FC10.2 | Immune profile response to rituximab in ROHHAD syndrome |
| 10:20 | FC10.3 | ROHHAD syndrome, thrombotic risk and endothelial damage: a single center experience. |
| 10:30 | FC10.4 | A Novel Mutation in RAI1 Gene in a Patient with Clinical Diagnosis of Rapid-Onset Obesity with Hypothalamic Dysregulation, Hypoventilation, and Autonomic Dysregulation (ROHHAD) Syndrome with Overlapping Symptoms of Smith Magenis Syndrome (SMS). |
| 10:40 | FC10.5 | MCM4 deficiency causing Natural Killer and Glucocorticoid Deficiency with DNA repair defect (AR-NKGCD) - a large cases series from the Irish Traveller Community |
| 10:50 | FC10.6 | PLACENTAL MEST GENE EXPRESSION IS ASSOCIATED WITH POSTNATAL GROWTH AND OBESITY |
| 11:00-11:30 | | Refreshment Break, Posters and Exhibition Exhibition Hall
|
| 11:30-12:00 | | Awards 2 ESPE Research Award Chair(s): Agnès Linglart (Paris, France) King Willem Alexander Auditorium
|
| 11:30 | | ESPE Research Award |
| 12:00-12:30 | | Plenary 4 Chair(s): Martine Cools (Ghent, Belgium) & Faisal Ahmed (Glasgow, UK) King Willem Alexander Auditorium
|
| 12:00 | | How AI will change medicine |
| 12:30-13:00 | | Awards 3 King Willem Alexander Auditorium
|
| | ESPE International Outstanding Clinician Award |
| | Outstanding Clinician Award |
| | ESPE Hormone Research in Paediatrics Prizes |
| | IFCAH-ESPE Award |
| 13:00-14:30 | | Lunch, posters and exhibition Exhibition Hall
|
| 13:20-14:20 | | Satellite Symposium 5 For more information please see satellite programme
|
| 14:30-15:30 | | Yearbook 2 Chair(s): Ken Ong (Cambridge, UK) Amazon
|
| 14:30 | YB2.1 | Puberty |
| 14:42 | YB2.2 | DSD and gender incongruence |
| 14:54 | YB2.3 | Oncology and Chronic Disease |
| 15:06 | YB2.4 | Diabetes Type 1 |
| 15:18 | YB2.5 | Editors' Choice |
| 14:30-16:00 | | Symposium 5 - Hypothalamic syndromes Chair(s): Herman Müller (Berlin, Germany) & Maithé Tauber (Toulouse, France) Mississippi
|
| 14:30 | S5.1 | Hypothalamic syndrome in Cancer survivors |
| 15:00 | S5.2 | The evolution of the hypothalamus |
| 15:30 | S5.3 | ROHHAD/ROHHADNET syndrome |
| 13:20-14:20 | | Satellite Symposium 6 For more information please see satellite programme
|
| 13:20-14:20 | | Satellite Symposium 7 For more information please see satellite programme
|
| 14:30-16:00 | | Symposium 6 - Neonatal endocrinology Chair(s): Khalid Hussain (Doha, Qatar) & Maria Güemes (Madrid, Spain) Yangtze 1&2
|
| 14:30 | S6.1 | Unravelling the role of epigenetics in reproductive adaptations to early-life environment |
| 15:00 | S6.2 | The role of insulin in prenatal programming of future metabolic disease |
| 15:30 | S6.3 | The development of the HPA axis of the newborn |
| 14:30-16:00 | | Symposium 7 - Theories of obesity development and their implications on dietary interventions Chair(s): Violeta Iotova (Varna, Bulgaria) & Ram Weiss (Jerusalem, Israel) Pacific
|
| 14:30 | S7.1 | Competing Paradigms of Obesity Pathogenesis |
| 15:00 | S7.2 | From the social life through the psyche and the brain to the epidemic expansion of the adipose mass |
| 15:30 | S7.3 | Polygenic risk score |
| 14:30-16:00 | | Symposium 8 - Adrenals Chair(s): Evangelia Charmandari (Athens, Greece) & Uta Neumann (Berlin, Germany) Atlantic
|
| 14:30 | S8.1 | Understanding the role of 11-oxygenated androgens |
| 15:00 | S8.2 | Adrenal cortex renewal in health and disease |
| 15:30 | S8.3 | Central nervous consequences of CAH and other adrenal disorders |
| 14:30-16:00 | | ESPE Nursing and Allied Health Working Group (PENS) Chair(s): Camilla Ernstsson (Umeå, Sweden), Clare Simpson (Leeds, UK) & Sandra Greetham (Hull, UK) Everest 1&2
|
| 14:30 | | Childhood craniopharyngioma - challenges for the pediatric endocrinologist |
| 15:00 | | The role of a nurse in managing and supporting children and their families with a craniopharyngioma - Roisin Boyle |
| 15:30 | | Q&A in Endocrine Nursing |
| 16:10-16:40 | | Plenary 5 Chair(s): Rasha Hamza (Cairo, Egypt) & Mehul Dattani (London, UK) King Willem Alexander Auditorium
|
| 16:10 | PL5 | Cracking the pituitary stem cell code across life using single-cell transcriptomics and organoid models |
| 16:40-17:00 | | Refreshment Break, Posters and Exhibition Exhibition Hall
|
| 17:00-18:30 | | Satellite Symposium 8 For more information please see satellite programme
|
| 17:00-18:30 | | Satellite Symposium 9 For more information please see satellite programme
|
| 17:00-18:30 | | Satellite Symposium 10 For more information please see satellite programme
|
| 18:30-19:45 | | ESPE Annual Business Meeting Pacific
|
Saturday 23 September |
| 07:15-18:30 | | Registration
|
| 08:00-08:45 | | Meet the Expert 3.2 Yangtze 1&2
|
| 08:00 | | Uncertainties around diagnosing growth hormone deficiency |
| 08:00-08:45 | | Meet the Expert 4.2 Pacific
|
| 08:00 | | Clinical Management of Prader-Willi Syndrome in infants, children and adolescents |
| 08:00-08:45 | | Meet the Expert 5.2 Everest 1&2
|
| 08:00 | | Management of Pituitary adenomas in Children |
| 08:00-08:45 | | Meet the Expert 8.2 Atlantic
|
| 08:00 | | Puberty induction in hypogonadism |
| 08:00-09:00 | | Yearbook 3 Chair(s): Christa Flück (Bern, Switzerland) & Ken Ong (Cambridge, UK) Amazon
|
| 08:00 | YB3.1 | Thyroid |
| 08:15 | YB3.2 | Growth and Growth Factors |
| 08:30 | YB3.3 | Bone, Growth Plate and Mineral Metabolism |
| 08:45 | YB3.4 | A tribute to Ze’ev Hochberg’s work |
| 09:00-10:30 | | How do I…? 2 Chair(s): Zdenek Sumnik (Prague, Czech Republic) & Saartje Straetemans (Maastricht, The Netherlands) King Willem Alexander Auditorium
|
| 09:00 | HDI2.1 | How to manage long term complications in T2DM in adolescents? |
| 09:30 | HDI2.2 | How Do I initiate and follow patients on a closed-loop system? |
| 10:00 | HDI2.3 | Diagnosis and management of hypercholesterolemia |
| 09:00-09:30 | | Rapid Free Communications 11: GH and IGFs Chair(s): Helen Storr (London, UK) & Christiaan de Bruin (Leiden, The Netherlands) Pacific
|
| 09:00 | RFC11.1 | The genetic aetiology of primary multiple pituitary hormone deficiency: a next-generation sequencing analysis of a single-centre cohort. |
| 09:05 | RFC11.2 | Are pappalysins and stanniocalcins involved in modifying the bioavailability of IGF-I in children with onset of type 1 diabetes mellitus? |
| 09:10 | RFC11.3 | Longitudinal assessment of health-related quality of life (HRQoL) & behavior in adults born small for gestational age (SGA) who were treated with growth hormone during childhood |
| 09:15 | RFC11.4 | Functional analysis of a novel mutation of IGF1R gene in two twins with growth failure. An example of genotype-phenotype heterogeneity. |
| 09:20 | RFC11.5 | Influence of sirtuin 1 and fibroblast growth factor 21 levels on IGF-1 concentration in children with short stature of different etiology |
| 09:25 | RFC11.6 | Evaluation Of The Growth Hormone-Insulin like Growth Factor1 Axis And Serum Fibroblast Growth Factor 21 Levels As Related To Stature In Children And Adolescents With Coeliac Disease Adherent To Gluten Free Diet |
| 09:00-09:30 | | Rapid Free Communications 12: Thyroid Chair(s): Athanasia Stoupa (Paris, France) & Joachim Pohlenz (Mainz, Germany) Mississippi
|
| 09:00 | RFC12.1 | Macro-TSH IgG complex in a case of Congenital Hypothyroidism (CH). |
| 09:05 | RFC12.2 | A novel frameshift mutation in Immunoglobulin Superfamily, Member 1 (IGSF1) causing central hypothyroidism, delayed puberty and GH deficiency |
| 09:10 | RFC12.3 | Thyroid disorders in childhood cancer survivors treated with 131 I-MIBG, TKIs or immune checkpoint inhibitors: incidence, mechanisms and clinical management – systematic review |
| 09:15 | RFC12.4 | Polyethylene glycol thyroid stimulating hormone (PEG-TSH) in real-life: a practical tool for solving a biochemical dilemma |
| 09:20 | RFC12.5 | Application of Shear Wave Elastography (SWE) in the ultrasound evaluation of thyroid nodules in children and adolescents |
| 09:25 | RFC12.6 | Phenylbutyrate treatment of three patients with Monocarboxylate Transporter 8 deficiency |
| 09:00-09:30 | | Rapid Free Communications 13: Pituitary, neuroendocrinology and puberty 2 Chair(s): Cynthia Andoniadou (London, UK) & Anne Rochtus (Leuven, Belgium) Atlantic
|
| 09:00 | RFC13.1 | Are Glucagon-like peptide-1 (GLP-1) receptor agonists a new treatment option for hypothalamic obesity in the paediatric population: Preliminary experience from a tertiary paediatric endocrine centre |
| 09:05 | RFC13.2 | Arginine-stimulated copeptin is independent of GH secretion status |
| 09:10 | RFC13.3 | Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care |
| 09:15 | RFC13.4 | Trio analyses of patients with congenital hypopituitarism reveals novel candidate genes |
| 09:20 | RFC13.5 | Growth hormone and TSH deficiency after [177Lu]Lu-DOTATATE therapy for pediatric neuroblastoma; description of a first case. |
| 09:25 | RFC13.6 | Pituitary size on volumetric MRI predicts the severity of the neuroendocrine phenotype in populations at risk |
| 09:00-09:30 | | Rapid Free Communications 14 - Late Breaking Chair(s): Annemarie Verrijn-Stuart (Utrecht, Netherlands) & Tommaso Aversa (Messina, Italy) Yangtze 1&2
|
| 09:00 | RFC14.1 | Clinical characteristics of patients presented with primary adrenal insufficiency due to a p.R451W mutation in the CYP11A1 gene |
| 09:05 | RFC14.2 | No Relationship Between Thyroid Function and ADHD – Results From a Nationwide Prospective Epidemiological Study and Mendelian Randomization |
| 09:10 | RFC14.3 | Body composition in a pediatric population with type 1 diabetes mellitus - The importance of planned physical activity |
| 09:15 | RFC14.4 | Evaluating the Effect of Recombinant Human Growth Hormone Treatment on Sleep-related Breathing Disorders in Toddlers with Prader–Willi Syndrome: a one-year retrospective cohort study. |
| 09:20 | RFC14.5 | Functional demonstration that variants in the C-terminal of IHH cause short stature and/brachdactyly |
| 09:25 | RFC14.6 | Enhanced histones acetylation in children with obesity: relationship with insulin resistance and inflammation |
| 09:30-10:30 | | Free Communications 11: GH and IGFs Chair(s): Helen Storr (London, UK) & Christiaan de Bruin (Leiden, The Netherlands) Pacific
|
| 09:30 | FC11.1 | GH replacement therapy with once-weekly somapacitan in children with GH deficiency is effective and well-tolerated: 2-year results from REAL4 |
| 09:40 | FC11.2 | Clinical characteristics of heterozygous ACAN gene variants and longer-term response to growth hormone treatment: real-world data |
| 09:50 | FC11.3 | Analysis of a large panel of genes in a cohort of patients with severe short stature: detection rate and genotype-phenotype correlations |
| 10:00 | FC11.4 | Long-term GH-treatment of children born small for gestational age (SGA) does not result in cerebrovascular abnormalities in adulthood compared to untreated controls |
| 10:10 | FC11.5 | Effective GH Replacement with Once-weekly Somapacitan in Japanese Children with GH Deficiency: 2-year Results from REAL4 |
| 10:20 | FC11.6 | Longitudinal analysis of the risk of brain tumour recurrence or progression in relation to the timing of commencement of growth hormone replacement therapy. |
| 09:30-10:30 | | Free Communications 12: Thyroid Chair(s): Juliane Leger (Paris, France) & Joachim Pohlenz (Mainz, Germany) Mississippi
|
| 09:30 | FC12.1 | Graves’ disease – are we just delaying the inevitable? |
| 09:40 | FC12.2 | Thyroid function analysis in 48 patients affected by severe combined immunodeficiency caused by adenosine deaminase deficiency |
| 09:50 | FC12.3 | Hypothyroidism due to IYD bi-allelic pathogenic variants: clinical description of eight patients |
| 10:00 | FC12.4 | Thyroid hormone resistance due to THRB gene mutations : neonatal manifestations in two cases |
| 10:10 | FC12.5 | Teprotumumab in an adolescent with severe corticosteroid-resistant Graves ophthalmopathy: success but unexpected neurological manifestations. |
| 10:20 | FC12.6 | TSH screening in premature newborns: a critical appraisal of the value of a second sample. |
| 09:30-10:30 | | Free Communications 13: Pituitary, neuroendocrinology and puberty 2 Chair(s): Cynthia Andoniadou (London, UK) & Anne Rochtus (Leuven, Belgium) Atlantic
|
| 09:30 | FC13.1 | Genetic evaluation in children with self-limited pubertal delay discloses new candidate genes |
| 09:40 | FC13.2 | Targeted gene panel screening in 144 congenital hypopituitarism patients, incorporating 135 known and novel genes implicated in hypopituitarism and/or hypothalamo-pituitary development. |
| 09:50 | FC13.3 | Variants in Methyl-CpG-binding protein 2 (MECP2) are associated with X-Linked Central Precocious Puberty |
| 10:00 | FC13.4 | Clinical and molecular genetic characteristics of 98 patients with congenital hypopituitarism: A single-center experience |
| 10:10 | FC13.5 | Systematic review and meta-analysis of spermatogenesis rates after pubertal induction with gonadotropins in males with hypogonadotropic hypogonadism |
| 10:20 | FC13.6 | Effects of Blue Light Exposure and Exposure Duration on Male Rats Puberty Process |
| 09:30-10:30 | | Free Communications 14 - Late Breaking Chair(s): Annemarie Verrijn-Stuart (Utrecht, The Netherlands) & Tommaso Aversa (Messina, Italy) Yangtze 1&2
|
| 09:30 | FC14.1 | Sleep health characteristics in children with congenital adrenal hyperplasia |
| 09:40 | FC14.2 | New Reference Values for Thyroid Volume by Ultrasound in German Children and Adolescents Under Iodine-Sufficient Conditions From a Nationwide Study |
| 09:50 | FC14.3 | Deconvolution Analysis: GH secretagogue (LUM-201) enhances growth in individuals with moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD) by enhancing endogenous GH secretion and increasing IGF-1 |
| 10:00 | FC14.4 | Improvement in insulin sensitivity and glucose metabolism in adolescents with obesity treated with once-weekly semaglutide 2.4 mg: a secondary analysis of the STEP TEENS trial |
| 10:10 | FC14.5 | Predicting Average IGF-I Concentration for Once-Weekly Somapacitan in Children with Growth Hormone Deficiency |
| 10:20 | FC14.6 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum |
| 10:30-11:00 | | Refreshment Break, Posters and Exhibition Exhibition Hall
|
| 11:00-11:30 | | Plenary 6 Chair(s): Michel Polak (Paris, France) & Paul van Trotsenburg (Amsterdam, The Netherlands) King Willem Alexander Auditorium
|
| 11:00 | PL6 | How the genome predicts human disease |
| 11:30-12:15 | | Awards 4 Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands) King Willem Alexander Auditorium
|
| 11:30 | | Andrea Prader Prize (30 mins) + ESPE International Award (15 mins) |
| 12:15-12:45 | | Plenary 7 Chair(s): Nils Krone (Sheffield, UK) & Malgorzata Wasniewska (Messina, Italy) King Willem Alexander Auditorium
|
| 12:15 | PL7 | Novel approaches in autoimmune endocrine disorders |
| 12:45-14:15 | | Lunch, posters and exhibition Exhibition Hall
|
| 14:00-14:45 | | Meet the Expert 2.2 Pacific
|
| 14:00 | | Informing children about their DSD - when and how? |
| 14:00-14:45 | | Meet the Expert 6.2 Mississippi
|
| 14:00 | | Approach to Thyroid cancer in Children |
| 14:00-14:45 | | Meet the Expert 7.2 Yangtze 1&2
|
| 14:00 | | Management of hyperinsulism beyond the acute phase |
| 14:15-15:00 | | Novel Advances 2 Chair(s): Daniëlle van der Kaay (Rotterdam, The Netherlands) & Agnes Linglart (Paris, France) Atlantic
|
| 14:15 | | DNA Methylation Episignatures: Defining Biomarkers of Rare Disorders |
| 14:15-15:15 | | Awards - Young Investigators Chair(s): Martine Cools (Ghent, Belgium) Amazon
|
| 14:15 | | ESPE Young Investigator Awards |
| 14:15 | | Research Unit Lecture |
| 14:15 | | Research Fellowship Lecture |
| 15:10-15:30 | | Refreshment Break, Posters and Exhibition Exhibition Hall
|
| 15:30-17:00 | | Symposium 9 - Thyroid Chair(s): Athanasia Stoupa (Paris, France) & Christiaan Mooij (Amsterdam, The Netherlands) Mississippi
|
| 15:30 | S9.1 | Central hypothyroidism due to mutations in IGSF1 - latest insights into its pathogenesis |
| 16:00 | S9.2 | Is there role for combined T4 and T3 therapy in hypothyroidism |
| 16:30 | S9.3 | The role of thyroid hormone transporters in brain development and function |
| 15:30-17:00 | | Symposium 10 - Bone Chair(s): Ola Nilsson (Stockholm, Sweden) & Gabriele Hartmann (Vienna, Austria) Yangtze 1&2
|
| 15:30 | S10.1 | Management of Fibrous dysplasia |
| 16:00 | S10.2 | Inherited ectopic calcification disorders |
| 16:30 | S10.3 | Life-time disease burden of achondroplasia |
| 15:30-17:00 | | Symposium 11 - Diet, nutrients and the environment Chair(s): Yael Lebenthal (Tel Aviv, Israel) & Edgar van Mil (Venlo, The Netherlands) Pacific
|
| 15:30 | S11.1 | Timing of eating and exercise to improve metabolic health in humans |
| 16:00 | S11.2 | Sugar and ultra-processed food |
| 16:30 | S11.3 | Weight loss and mechanisms of weight regain |
| 15:30-17:00 | | Symposium 12: What's new for the HPG Axis Chair(s): Sasha Howard (London, UK) & Anne Simone Parent (Liege, Belgium) Atlantic
|
| 15:30 | S12.1 | Minipuberty - Looking into the future |
| 16:00 | S12.2 | SEMA6A drives GnRH neuron-dependent puberty onset by tuning median eminence vascular permeability. |
| 16:30 | S12.3 | Recent advances in our understanding of the regulation of GnRH secretion |
| 17:05-17:35 | | Plenary 8 Chair(s): Indi Banerjee (Manchester, UK) & Tadej Battelino (Ljubljana, Slovenia) King Willem Alexander Auditorium
|
| 17:05 | PL8 | Real world use of closed loop insulin delivery |
| 17:35-17:50 | | Awards 5 - ESPE Meeting Host Poster Awards Chair(s): Paul van Trotsenburg (Amsterdam, The Netherlands) King Willem Alexander Auditorium
|
| 17:55-18:10 | | Closing Ceremony King Willem Alexander Auditorium
|